Will the split improve the stock's eligibility for inclusion in indices or institutional mandates?

Impact on Index Eligibility and Institutional Mandates

A 1‑for‑19 reverse split lifts Catheter Precision’s (VTAK) share price roughly 19‑fold, moving it well above the typical $5‑$10 minimum price threshold imposed by many equity‑index providers (e.g., S&P 500, Russell 3000) and by most institutional mandate screens. The higher per‑share price also helps the stock clear the “minimum price” hurdles that many mutual‑fund and ETF managers enforce to avoid “penny‑stock” restrictions, making VTAK a viable candidate for inclusion in broader market or sector‑specific indexes that require a minimum trading price and a minimum float. Because the split does not change market‑cap, the company’s weight in any index would remain the same, but the higher price eliminates the immediate disqualifier that could have excluded it from a portfolio that is barred from sub‑$5 securities.

Trading Implications

• Short‑term: Expect a modest, temporary uptick in volume as index‑tracking funds and quantitative models that screen for price thresholds rebalance to include VTAK. Expect bid‑ask spreads to narrow as liquidity improves.
• Medium‑term: If the company can sustain the higher price and meet the liquidity thresholds (average daily volume > 1 M shares or ≥ $2 M in daily dollar volume), it will become eligible for a broader set of institutional mandates, potentially driving a modest “inclusion premium” of 2‑5 % as new demand builds.
• Action: Consider buying on the first day of post‑split trading if the price remains above the historic split‑adjusted levels and volume supports a stable market. Keep an eye on the company’s upcoming earnings and any subsequent index‑review announcements—these will be the true catalysts for sustained institutional interest.